Madrigal Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Madrigal Pharmaceuticals

MDGL 418.90

-2.0%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (116)	7/22/2019 1:36:49 PM
From: Miljenko Zuanic	Read Replies (1) of 138

<about my very poor judgement > on company and managements....and first orange (red) flag was when they started talking about drug response relative to exposure (high-exposure sub-population, HOW????) and signaling...after all that ROCHE did with PK/PD studies, WE (MDGL) still do not have idea what is going on! Regards the secondary, Dec-17 (at 83) or Jun-2018 (at 305)? For that POORE execution (amount of the offer and $$$ needed to complete business up to approval/marketing) CFO would finish his career (IF I am CEO) at Staljin concentration camp in Siberia. Sadly, somehow I still believe that selective THR-beta agonist will have utility on NASH/metabolic, so holding my position steady (at significant loss).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next